On November 5, 2021, the pharmaceutical firm Pfizer Inc. announced the results of a clinical trial investigating the effectiveness of an antiviral medication in the form of a pill, ritonavir, in the treatment of people with mild-to-moderate (non-hospitalized) COVID-19 who were considered high risk for severe disease because of health problems such as obesity, diabetes or heart disease. According to reports of the study, 3 of 389 recipients of the treatment were ultimately hospitalized or died, while 27 of 385 recipients of a placebo were ultimately hospitalized or died (in fact, no recipients of the treatment died). Is the hospitalization/death rate for recipients of the treatment significantly different from that for recipients of the placebo? Carefully state the hypotheses that you are testing and the test that you are using. Use = .01. What assumptions are you making in performing this test?